RecruitingNCT06392217
clinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone Metastases
Real-world Study of Incadronate in Breast Cancer Patients With Metastatic Bone Disease: clinIcal Efficacy and Safety
Sponsor
Fudan University
Enrollment
500 participants
Start Date
Mar 12, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This is a real-world study to explore the efficacy and safety of incadronate in the treatment of breast cancer patients with bone metastases.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is testing the effectiveness and safety of a drug called incadronate — a type of bisphosphonate that helps protect bones — in people with breast cancer that has spread to the bones. Bone metastases can cause pain, fractures, and other serious complications.
**You may be eligible if...**
- You are 18 or older
- You have been diagnosed with breast cancer that has spread to the bones (confirmed by imaging or biopsy)
- You are in generally good health (ECOG score of 3 or lower)
- You have no serious heart disease
- You are willing to use contraception throughout the study and for 6 months after
**You may NOT be eligible if...**
- You are pregnant or breastfeeding
- You have another active serious disease or infection
- You have had another type of cancer in the past 5 years (except certain curable cancers)
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06392217
Related Trials
Genomic Services Research Program
NCT025959571 location
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT052833304 locations
A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)
NCT070671381 location
Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)
NCT068852031 location
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT06103864316 locations